Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart valve patients: should you stop your Beta-Blocker before surgery?

NCT ID NCT06472934

Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether it is safe to temporarily stop taking beta-blockers before a procedure called transcatheter aortic valve replacement (TAVR) for severe aortic stenosis. About 498 adults who are scheduled for TAVR and have been on beta-blockers for at least a month will be randomly assigned to either pause or continue their medication. Researchers will track deaths, hospital readmissions for heart failure, strokes, and serious heart rhythm problems within 30 days after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
beta-blocker discontinuation
What this could lead to
If successful, this could show that temporarily stopping beta-blockers before TAVR is safe, potentially simplifying care for patients.
What could go wrong
This is a mid-sized trial, not a large Phase 3 study. Results may not apply to all patients, and pausing beta-blockers could increase risk of arrhythmias or heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 498 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Informed Consent must be signed by the subject prior to any study intervention. * Adult patients (\> 18 years) with severe symptomatic aortic stenosis eligible and scheduled for elective TAVR and are able to give consentand are able to give consent * Indication for B-blocker therapy with a prior treatment duration of at least 1 month before inclusion. Exclusion Criteria: * Emergency or urgent indication for TAVR. * Hemodynamically unstable patients receiving inotropic medication. * Prior permanent pacemaker implantation. * Existing indication for pacemaker implantation. * Hemodynamic relevant left ventricular outflow tract obstruction. * Prior intolerance of B-blocker medication. * Life expectancy \< 1 year. * Known or suspected non-compliance, drug, or alcohol abuse. * Inability to give consent, or follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant. * Being in a dependent relationship with the trial site * Participation in another study with investigational drug within the 30 days preceding and during the present study. * Previous enrolment into the current study. * Pregnancy or breast feeding women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aortic stenosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aortic stenosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Geneva University Hospitals

    RECRUITING

    Geneva, 1205, Switzerland

  • Herz- und Diabeteszentrum NRW Universitätsklinik

    RECRUITING

    Bad Oeynhausen, 32545, Germany

  • Inselspital, Bern University Hospital

    RECRUITING

    Bern, 3010, Switzerland

  • Kerckhoff-Klinik GmbH

    RECRUITING

    Bad Nauheim, 61231, Germany

  • Medical University of Graz

    RECRUITING

    Graz, 8036, Austria

  • University Hospital Basel

    RECRUITING

    Basel, 4031, Switzerland

  • University Hospital Salzburg

    RECRUITING

    Salzburg, 5020, Austria

  • University Hospital of Zürich

    RECRUITING

    Zurich, 8091, Switzerland

  • University Medical Center Freiburg

    RECRUITING

    Bad Krozingen, 79189, Germany

  • Universitätsklinikum Giessen und Marburg GmbH

    RECRUITING

    Giessen, 35392, Germany

  • Universitätsklinikum Schleswig-Holstein AöR

    RECRUITING

    Kiel, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.